Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2015 - 2026)

Biomarin Pharmaceutical (BMRN) has 12 years of Amortization of Deferred Charges data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 22440.74% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 653.1% YoY) and the FY2025 annual result came in at $2.6 million, down 21.94% from the prior year.
• Amortization of Deferred Charges improved to $6.1 million in Q1 2026, from $653000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $6.1 million in Q1 2026 to a low of $27000.0 in Q1 2025.
• A 5-year average of $785764.7 and a median of $149000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2025 — Amortization of Deferred Charges slumped 97.27% — and 2026, when it surged 22440.74%.
• Tracing BMRN's Amortization of Deferred Charges over 5 years: stood at $1.0 million in 2022, then dropped by 3.7% to $990000.0 in 2023, then plunged by 33.33% to $660000.0 in 2024, then retreated by 1.06% to $653000.0 in 2025, then surged by 832.01% to $6.1 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $6.1 million (Q1 2026), $653000.0 (Q4 2025), and $27000.0 (Q3 2025), per Business Quant data.